Financhill
Back

Celldex Therapeutics Quote, Financials, Valuation and Earnings

U.S. Government Report Alert Tuesday

Discover the Secret Loophole
Sell
33

CLDX
Celldex Therapeutics

Last Price:
25.39
Seasonality Move:
16.03%

7 Day Trial

ALL ACCESS PASS

$ 7

Write This Down: Tuesday at 2 p.m. ET!

Don't Miss Our LIVE Trade

Celldex Therapeutics Price Quote

$25.39
-0.29 (-1.13%)
(Updated: November 4, 2024 at 5:55 PM ET)

Celldex Therapeutics Key Stats

Sell
33
Celldex Therapeutics (CLDX) is a Sell

Day range:
$25.29 - $26.88
52-week range:
$24.72 - $53.18
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
173.39
P/B ratio:
2.09%

Volume:
1.1M
Avg. volume:
1.4M
1-year change:
8.95%
Market cap:
$1.7B
Revenue:
$6.9M
EPS:
$-2.75

How Much Does Celldex Therapeutics Make?

Is Celldex Therapeutics Growing As A Company?

  • What Is Celldex Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 8.32%
  • What Is Celldex Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Celldex Therapeutics Stock Price Performance

What Is Celldex Therapeutics 52-Week High & Low?

Celldex Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Celldex Therapeutics?

Is Celldex Therapeutics Cash Flow Positive?

  • What Is CLDX Cash Flow From Operations?
    Cash flow from operations (TTM) is -$121.5M
  • What Is Celldex Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $657.5M
  • What Is Celldex Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$521.4M

Celldex Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    CLDX return on invested capital is -28.83%
  • What Is Celldex Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -27.22%
  • What Is CLDX Return On Equity?
    ROE is a measure of profitability and is -28.83%

Celldex Therapeutics Earnings Date & Stock Price

Celldex Therapeutics Competitors

Celldex Therapeutics Dividend Yield

Celldex Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 8.99%
Revenue: 832.09% 192.41%

Analyst Recommendations

Buy Recommendations: 9
Hold Recommendations: 2
Sell Recommendations: 0
Price Target: 67.40
Upside from Last Price: 162.46%

Major Shareholders

  • How many CLDX shares are owned by institutional investors?
    119.6M CLDX shares are owned by institutional investors
  • How many CLDX shares are owned by insiders?
    6.7M CLDX shares are owned by insiders